CN114622019A - Birc5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用 - Google Patents
Birc5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用 Download PDFInfo
- Publication number
- CN114622019A CN114622019A CN202210290234.9A CN202210290234A CN114622019A CN 114622019 A CN114622019 A CN 114622019A CN 202210290234 A CN202210290234 A CN 202210290234A CN 114622019 A CN114622019 A CN 114622019A
- Authority
- CN
- China
- Prior art keywords
- stem cells
- birc5
- gene
- mesenchymal stem
- osteogenic differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150115284 BIRC5 gene Proteins 0.000 title claims abstract description 62
- 230000009818 osteogenic differentiation Effects 0.000 title claims abstract description 43
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 30
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 22
- 239000003112 inhibitor Substances 0.000 title claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 108010002687 Survivin Proteins 0.000 description 13
- 102000000763 Survivin Human genes 0.000 description 12
- 230000002018 overexpression Effects 0.000 description 11
- 102100021253 Antileukoproteinase Human genes 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 230000008021 deposition Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000010201 enrichment analysis Methods 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用，本发明还设计了用于检测人骨髓间充质干细胞中BIRC5基因表达量的试剂盒。本发明首次证明了BIRC5基因在人骨髓间充质干细胞中的作用，且证明BIRC5基因能够有效抑制人骨髓间充质干细胞的成骨分化，因此，BIRC5基因能够作为人骨髓间充质干细胞成骨分化抑制剂，进而来抑制人骨髓间充质干细胞成骨分化。
Description
技术领域
本发明属于人骨髓间充质干细胞成骨分化抑制剂技术领域，具体涉及BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用。
背景技术
骨、软骨、肌腱等组织缺损修复具有重大临床需求，但因缺乏理想修复供体，目前治疗方法存在创伤大、供体严重不足等弊端。因此，对于这类骨疾病的最佳治疗方式是采用组织工程骨。成骨支架、种子细胞及高效的骨分化诱导因子是组织工程目前的研究热点。人骨髓间充质干细胞（hBMSCs）是一种多能成体干细胞，是组织工程中重要的种子细胞来源。研究hBMSCs的成骨分化生物学效应及其具体的分子机制可为骨质疏松症、骨肿瘤及骨折等疾病提供新的治疗靶点。
发明内容
本发明的目的是提供了BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用，其中BIRC5是蛋白编码基因，该基因是凋亡抑制剂（IAP）基因家族的成员，该家族编码可防止细胞凋亡的负调节蛋白，本发明通过实验证实BIRC5基因与hBMSCs的成骨分化现象呈负相关，且BIRC5基因与人骨髓间充质干细胞成骨分化的标志性基因表达也呈负相关；同时本发明设计了BIRC5基因（Homo sapiens Gene ID:332）表达量检测的试剂盒。
本发明为实现上述目的采用如下技术，BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用。
进一步限定，所述BIRC5基因与人骨髓间充质干细胞成骨分化现象呈负相关，且BIRC5基因与人骨髓间充质干细胞成骨分化的标志性基因表达也呈负相关。
进一步限定，用于检测人骨髓间充质干细胞中BIRC5基因表达量的试剂盒，其特征在于包含特异性扩增BIRC5基因的引物；
引物中正向引物序列为：
5'- GGACCACCGCATCTCTACATT-3'；
引物中反向引物序列为：
5'- TTTCCTTTGCATGGGGTCGT-3'。
本发明与现有技术相比具有以下优点和有益效果：本发明首次证明了BIRC5基因在人骨髓间充质干细胞中的作用，且证明BIRC5基因能够有效抑制人骨髓间充质干细胞的成骨分化，因此，BIRC5基因能够作为人骨髓间充质干细胞成骨分化抑制剂，进而来抑制人骨髓间充质干细胞成骨分化。
附图说明
图1是hBMSCs诱导的成骨细胞中，BIRC5基因表达显著下调；
图2是hBMSCs中运用慢病毒质粒转染高表达BIRC5基因；
图3是与BIRC5基因可能发生的蛋白和转录调控网络；
图4是数据集GSE80614中，与BIRC5基因正相关和负相关的基因表达热图；
图5是BIRC5基因的GO和KEGG信号富集分析；
图6是BIRC5基因可抑制hBMSCs的成骨分化，并且与成骨分化标志基因的表达呈负相关；
图7是BIRC5基因可抑制hBMSCs的成骨分化现象；
图8是BIRC5基因影响了hBMSCs中ALP含量，进而可影响hBMSCs成骨分化；
图9是BIRC5基因影响hBMSCs钙沉积，进而可影响其成骨分化。
具体实施方式
结合附图详细描述本发明的技术方案。
实施例1
本实施例用于说明在人骨髓间充质干细胞（hBMSCs）诱导的成骨细胞中，BIRC5基因表达降低。
A、数据下载和整理。利用NCBI网站的GEO数据库的3个人骨髓来源间充质干细胞成骨分化数据集GSE80614、GSE12266和GSE18043进行分析成骨分化后的差异基因。选取至少有两个数据集中表达差异的基因为靶基因，并进行生物信息学分析。如图1中A所示，BIRC5基因在GSE80614和GSE12266中呈现低表达状态。****p <0.0001，*p <0.05，NA P>=0.05。
B、qPCR验证hBMSCs成骨诱导7天（OS-7d）后，与未诱导的细胞（control）相比较BIRC5基因表达显著降低。***p <0.001。
实施例2
本实施例用于说明在人骨髓间充质干细胞（hBMSCs）中运用慢病毒质粒转染高表达BIRC5基因。
A、运用PLV-N-Flag载体，构建慢病毒过表达BIRC5质粒，并与293细胞中包装后转染hBMSCs。
B、qPCR检测BIRC5过表达效率。**p <0.001。
实施例3
本实施例用于说明与BIRC5基因可能发生的蛋白和转录调控网络。
利用string网站构建BIRC5的蛋白互作PPI网络，Cytoscape软件进行可视化作图。使用数据库RegNetwork（http://www.regnetworkweb.org/）预测BIRC5基因基因上游的miRNA和转录因子，构建靶基因调控网络。图3是BIRC5基因可能发生的蛋白和转录调控网络，图中三角形表示miRNA，正方形表示转录因子。
实施例4
本实施例用于说明与BIRC5基因正相关和负相关的基因表达热图。
利用R语言软件包，使用GSE80614中的成骨诱导组（OS）数据进行BIRC5基因与所有基因的相关性分析，并分别展示正相关和负相关的基因表达热图。如图4所示，（A）GSE80614中与BIRC5基因正相关表达热图；（B）GSE80614中与BIRC5基因负相关的基因表达热图。
实施例5
本实施例用于验证BIRC5基因的GO和KEGG富集分析。
利用R软件包进行BIRC5基因的GO和KEGG分析。可见BIRC5基因可富集于细胞发育、细胞周期以及细胞外刺激等信号系统。如图5所示，其中图5中A为GO分析的波浪图；图5中B为KEGG分析的气泡图。图5说明BIRC5基因的GO和KEGG信号富集分析，为研究其调控成骨分化的分子机制提供理论基础。
实施例6
本实施例用于说明BIRC5基因可抑制hBMSCs的成骨分化，并且与成骨分化标志基因的表达呈负相关。
利用慢病毒过表达BIRC5质粒转染hBMSCs，qPCR实验方法验证成骨分化标志性基因Runx2、OPN、OSX和OCN基因的表达。如图6所示，过表达BIRC5基因后，Runx2、OPN、OSX和OCN基因的表达显著降下调。其中control为对照组，OS-7d是成骨诱导7天组；V- BIRC5是过表达BIRC5组。*p<0.05,**p<0.01,***p<0.001。图6说明BIRC5基因可抑制hBMSCs的成骨分化，并且与成骨分化标志基因表达呈负相关。
实施例7
本实施例用于说明BIRC5基因可抑制hBMSCs的成骨分化现象。
利用ALP活性检测试剂盒和钙含量检测试剂盒检测hBMSCs对照组、OS-7d组和过表达BIRC5（B-V）的ALP活性和钙沉积情况。结果如图7所示，图7中A说明过表达BIRC5基因，与诱导组相比较，可相对降低ALP活性，**p<0.01。图7中B说明过表达BIRC5基因，与诱导组相比较，可降低细胞钙的沉积，***p<0.001。图7说明BIRC5基因参与调控hBMSCs的成骨分化程度，可抑制成骨分化作用。
实施例8
本实施例用于说明BIRC5基因抑制了hBMSCs的成骨分化作用。
利用ALP染色检测试剂盒，检测对照组、OS-7d组和过表达BIRC5组（V-BIRC5）组中ALP的含量。如图8所示，通过显色反应表明过表达BIRC5基因减弱了ALP的染色强度。图8说明BIRC5基因影响了hBMSCs中ALP含量，进而可影响hBMSCs成骨分化。
实施例9
本实施例用于说明过表达BIRC5基因减少hBMSCs钙沉积，进而可抑制其成骨分化作用。
利用茜素红（ARS）染色的实验方法，检测对照组、成骨诱导10天（OS-10d）组和过表达BIRC5组（V- BIRC5）组中钙沉积情况。如图9所示，过表达BIRC5基因减弱了ARS的染色强度。图9说明书BIRC5基因影响了hBMSCs钙沉积，进而可影响其成骨分化。
表1 荧光定量RT-PCR引物序列
以上显示和描述了本发明的基本原理，主要特征和优点，在不脱离本发明精神和范围的前提下，本发明还有各种变化和改进，这些变化和改进都落入要求保护的本发明的范围。
SEQUENCE LISTING
<110> 新乡医学院
<120> BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用
<130> 2022
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 21
<212> DNA
<213> 人工序列（artificial sequence）
<400> 1
ggaccaccgc atctctacat t 21
<210> 2
<211> 20
<212> DNA
<213> 人工序列（artificial sequence）
<400> 2
tttcctttgc atggggtcgt 20
序列表
<110> 新乡医学院
<120> BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用
<130> 2022
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 1
ggaccaccgc atctctacat t 21
<210> 2
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 2
tttcctttgc atggggtcgt 20
Claims (3)
1.BIRC5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用。
2.根据权利要求1所述的应用，其特征在于：所述BIRC5基因与人骨髓间充质干细胞成骨分化现象呈负相关，且BIRC5基因与人骨髓间充质干细胞成骨分化的标志性基因表达也呈负相关。
3.一种用于检测人骨髓间充质干细胞中BIRC5基因表达量的试剂盒，其特征在于包含特异性扩增BIRC5基因的引物；
引物中正向引物序列为：
5'- GGACCACCGCATCTCTACATT-3'；
引物中反向引物序列为：
5'- TTTCCTTTGCATGGGGTCGT-3'。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210290234.9A CN114622019A (zh) | 2022-03-23 | 2022-03-23 | Birc5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210290234.9A CN114622019A (zh) | 2022-03-23 | 2022-03-23 | Birc5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114622019A true CN114622019A (zh) | 2022-06-14 |
Family
ID=81903473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210290234.9A Pending CN114622019A (zh) | 2022-03-23 | 2022-03-23 | Birc5基因作为人骨髓间充质干细胞成骨分化抑制剂的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114622019A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761749A (zh) * | 2003-03-10 | 2006-04-19 | 独立行政法人科学技术振兴机构 | 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法 |
| CN104388384A (zh) * | 2014-10-29 | 2015-03-04 | 河南省华隆生物技术有限公司 | 氧化型低密度脂蛋白在诱导骨髓间充质干细胞向心肌样细胞分化的应用 |
-
2022
- 2022-03-23 CN CN202210290234.9A patent/CN114622019A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761749A (zh) * | 2003-03-10 | 2006-04-19 | 独立行政法人科学技术振兴机构 | 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法 |
| US20060166214A1 (en) * | 2003-03-10 | 2006-07-27 | Yukio Kato | Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker |
| CN104388384A (zh) * | 2014-10-29 | 2015-03-04 | 河南省华隆生物技术有限公司 | 氧化型低密度脂蛋白在诱导骨髓间充质干细胞向心肌样细胞分化的应用 |
Non-Patent Citations (4)
| Title |
|---|
| PRATIBHA SINGH 等: "Survivin Is a Master Regulator of Mesenchymal Stem Cell Functions and Potential Therapeutic Target for Mesenchymal Stem Cell Expansion", 《BLOOD BLOOD》, vol. 124, no. 21, pages 774, XP086739541, DOI: 10.1182/blood.V124.21.774.774 * |
| PRATIBHA SINGH 等: "Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function", 《STEM CELLS》, vol. 36, pages 125 * |
| 周青松 等: "慢病毒介导survivin 体外转染MSCs 及功能测定", 《细胞与分子免疫学杂志》, vol. 27, no. 10, pages 1139 - 1142 * |
| 赵立强 等: "siRNA 沉默Survivin 基因对鼻咽癌CNE-2 细胞凋亡的影响", 《基因组学与应用生物学》, vol. 36, no. 5, pages 1690 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Long et al. | miR-381 modulates human bone mesenchymal stromal cells (BMSCs) osteogenesis via suppressing Wnt signaling pathway during atrophic nonunion development | |
| Tu et al. | MiR-142-5p promotes bone repair by maintaining osteoblast activity | |
| Chen et al. | Long non‑coding RNA XIST promotes osteoporosis through inhibiting bone marrow mesenchymal stem cell differentiation | |
| Feng et al. | LncRNA GAS5 overexpression alleviates the development of osteoporosis through promoting osteogenic differentiation of MSCs via targeting microRNA-498 to regulate RUNX2. | |
| Huang et al. | miR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2 | |
| Heo et al. | Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells | |
| Lv et al. | MicroRNA-200a-3p accelerates the progression of osteoporosis by targeting glutaminase to inhibit osteogenic differentiation of bone marrow mesenchymal stem cells | |
| Jin et al. | MicroRNA-145 suppresses osteogenic differentiation of human jaw bone marrow mesenchymal stem cells partially via targeting semaphorin 3A | |
| Dai et al. | MicroRNA‑31 promotes chondrocyte proliferation by targeting C‑X‑C motif chemokine ligand 12 | |
| Jiang et al. | Effects of lncRNA DANCR on proliferation and differentiation of osteoblasts by regulating the Wnt/β-catenin pathway. | |
| Choi et al. | Transcriptional profiling of human femoral mesenchymal stem cells in osteoporosis and its association with adipogenesis | |
| Zhao et al. | miR-129-5p promotes osteogenic differentiation of BMSCs and bone regeneration via repressing Dkk3 | |
| Dai et al. | LncRNA H19 regulates BMP2-induced hypertrophic differentiation of mesenchymal stem cells by promoting Runx2 phosphorylation | |
| Ye et al. | IRF2‐mediated upregulation of lncRNA HHAS1 facilitates the osteogenic differentiation of bone marrow‐derived mesenchymal stem cells by acting as a competing endogenous RNA | |
| Zhao et al. | Effects of platelet-derived growth factor on chondrocyte proliferation, migration and apoptosis via regulation of GIT1 expression | |
| Wang et al. | Optogenetic control of mesenchymal cell fate towards precise bone regeneration | |
| Mei et al. | MicroRNA miR-874-3p inhibits osteoporosis by targeting leptin (LEP) | |
| Dong et al. | The influence of MicroRNA‐150 in Osteoblast Matrix Mineralization | |
| Jiang et al. | miR‑204 inhibits the osteogenic differentiation of mesenchymal stem cells by targeting bone morphogenetic protein 2 | |
| Lei et al. | Teriparatide alleviates osteoporosis by promoting osteogenic differentiation of hMSCs via miR-375/RUNX2 axis. | |
| Ma et al. | Human amnion-derived mesenchymal stem cells promote osteogenic differentiation of human bone marrow mesenchymal stem cells via H19/miR-675/APC axis | |
| Zhou et al. | MicroRNA-1286 inhibits osteogenic differentiation of mesenchymal stem cells to promote the progression of osteoporosis via regulating FZD4 expression. | |
| Chen et al. | Downregulated microRNA-23b promotes BMP9-mediated osteogenesis in C2C12 myoblast cells by targeting Runx2 | |
| Zhou et al. | Stanniocalcin 2 improved osteoblast differentiation via phosphorylation of ERK | |
| Li et al. | The roles of long non-coding RNA in osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |